IP Library › Granted Patent US 12,655,196
Granted Patent B2
US 12,655,196 · App. 18/516,130 · Granted Jun 16, 2026

MHC multimers, methods for their generation, labeling and use

Inventors: Liselotte Brix (Bagsværd, DK); Henrik Pedersen (Lynge, DK); Tina Jakobsen (Ballerup, DK); Jørgen Schøller (Lyngby, DK); Jesper Lohse (Copenhagen NV, DK); Katja Brunstedt (Lyngby, DK); Kivin Jacobsen (Hvalså, DK)
Assignee: Agilent Technologies, Inc.
C07K14/70539A61K47/61A61K47/6425A61K47/665B82Y5/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,196
App. No.
18/516,130
Granted
Jun 16, 2026
Kind
B2
Abstract

The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.

Claims (13)

1 . A composition comprising a plurality of MHC multimers and a carrier, wherein each MHC multimer comprises (a-b-P) n , wherein n>1, wherein a and b together form a functional MHC protein capable of binding the peptide P, when P is present;

wherein (a-b-P) is the MHC-peptide complex formed when the peptide P binds to the functional MHC protein;

wherein each MHC protein or MHC-peptide complex is associated with one or more multimerization domains;

wherein said MHC multimer comprises one or more labels;

wherein the composition comprises groups of MHC multimers, wherein MHC multimers of some of said groups comprise one or more same labels within the group and MHC multimers of others of said groups each comprise two or more different labels within the group, wherein each group of MHC multimers presents a different peptide compared to other groups;

wherein the MHC multimers of each group are labelled with said one or more same labels or said two or more different labels;

wherein the composition is made by a process comprising providing a plurality of said MHC-peptide complexes and associating them with said one or more multimerization domains.

2 . The composition according to claim 1 , wherein said labels are selected from the group consisting of fluorophores, chromophores, electrochemiluminescent labels, bioluminescent labels, polymers, polymer particles, bead or other solid surfaces, metal particles, spin labels, radioisotopes, enzyme substrates, haptens, antigens, quantum dots, aminohexyl, pyrene, nucleic acids or nucleic acid analogs, peptide ligands or substrates, enzymes, antibodies and antibody fragments.

3 . The composition according to claim 1 , wherein said labels are fluorescent labels.

4 . The composition according to claim 1 , wherein the labels are attached directly to the MHC multimer, or wherein the labels are attached indirectly to the MHC multimer.

5 . The composition according to claim 4 , wherein the labels are attached indirectly via one or more marker molecules carrying one or more labels.

6 . The composition according to claim 1 , wherein the labels are covalently attached to the MHC multimer; or wherein the labels are non-covalently attached to the MHC multimer.

7 . The composition according to claim 1 , wherein one or more MHC-peptide complexes are covalently linked to the one or more multimerization domains.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2023
From: DAKO DENMARK APS
To: AGILENT TECHNOLOGIES, INC.
Reel/Frame 065752/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2023
From: BRIX, LISELOTTE; PEDERSEN, HENRIK; JAKOBSEN, TINA; SCHØLLER, JØRGEN; LOHSE, JESPER; BRUNSTEDT, KATJA; JACOBSEN, KIVIN
To: DAKO DENMARK A/S
Reel/Frame 065761/0992 →
CHANGE OF NAME Recorded Dec 4, 2023
From: DAKO DENMARK A/S
To: DAKO DENMARK APS
Reel/Frame 065762/0022 →
Priority Claims (4)
DK PA 2007 00972 · Jul 3, 2007 · national
DK PA 2007 00973 · Jul 3, 2007 · national
DK PA 2007 00974 · Jul 3, 2007 · national
DK PA 2007 00975 · Jul 3, 2007 · national
Continuity (8)
Continuation 16015955 · Jun 22, 2018
Continuation 12644554 · Dec 22, 2009
Continuation PCTDK2008050167 · Jul 3, 2008
Provisional Application 60929583 · Jul 3, 2007
Provisional Application 60929581 · Jul 3, 2007
Provisional Application 60929586 · Jul 3, 2007
Provisional Application 60929582 · Jul 3, 2007
Related Publication 20240150431A1 · May 9, 2024
References Cited (400)
US 4281061A · Zuk et al. · 1981 [cited by applicant]
US 4336173A · Ugelstad · 1982 [cited by applicant]
US 4387164A · Hevey et al. · 1983 [cited by applicant]
US 4459378A · Ugelstad · 1984 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4654267A · Ugelstad et al. · 1987 [cited by applicant]
US 4876190A · Recktenwald · 1989 [cited by applicant]
US 4994373A · Stavrianopoulos et al. · 1991 [cited by applicant]
US 5039487A · Smith · 1991 [cited by applicant]
US 5130297A · Sharma et al. · 1992 [cited by applicant]
US 5194425A · Sharma et al. · 1993 [cited by applicant]
US 5260422A · Clark et al. · 1993 [cited by applicant]
US 5284935A · Clark et al. · 1994 [cited by applicant]
US 5312744A · Shibata · 1994 [cited by applicant]
US 5468481A · Sharma et al. · 1995 [cited by applicant]
US 5543332A · Lihme et al. · 1996 [cited by applicant]
US 5583031A · Stern · 1996 [cited by applicant]
US 5627037A · Ward et al. · 1997 [cited by applicant]
US 5635363A · Altman et al. · 1997 [cited by applicant]
US 5652342A · Zimmerman et al. · 1997 [cited by applicant]
US 5807552A · Stanton et al. · 1998 [cited by applicant]
US 5869270A · Rhode et al. · 1999 [cited by applicant]
US 5891741A · Siiman et al. · 1999 [cited by applicant]
US 5955079A · Mond et al. · 1999 [cited by applicant]
US 5994089A · Siiman et al. · 1999 [cited by applicant]
US 5998204A · Tsien et al. · 1999 [cited by applicant]
US 6015884A · Schneck et al. · 2000 [cited by applicant]
US 6074645A · Diamond et al. · 2000 [cited by applicant]
US 6090587A · Rhode et al. · 2000 [cited by applicant]
US 6096315A · Zimmerman et al. · 2000 [cited by applicant]
US 6106840A · Clark et al. · 2000 [cited by applicant]
US 6129916A · Chang · 2000 [cited by applicant]
US 6140113A · Schneck et al. · 2000 [cited by applicant]
US 6156317A · Diamond et al. · 2000 [cited by applicant]
US 6156514A · Acevedo et al. · 2000 [cited by applicant]
US 6197302B1 · Hirsh et al. · 2001 [cited by applicant]
US 6197928B1 · Tsien et al. · 2001 [cited by applicant]
US 6211342B1 · Hirsh et al. · 2001 [cited by applicant]
US 6232445B1 · Rhode et al. · 2001 [cited by applicant]
US 6248564B1 · Walter et al. · 2001 [cited by applicant]
US 6251399B1 · Diamond et al. · 2001 [cited by applicant]
US 6268411B1 · Schneck et al. · 2001 [cited by applicant]
US 6306605B1 · Acevedo et al. · 2001 [cited by applicant]
US 6309645B1 · Rhode et al. · 2001 [cited by applicant]
US 6335173B1 · Kaplan · 2002 [cited by applicant]
US 6387622B1 · Siiman et al. · 2002 [cited by applicant]
US 6413934B1 · Stayton et al. · 2002 [cited by applicant]
US 6448071B1 · Schneck et al. · 2002 [cited by applicant]
US 6451314B1 · Clark et al. · 2002 [cited by applicant]
US 6451769B1 · Huebner et al. · 2002 [cited by applicant]
US 6458354B1 · Schneck et al. · 2002 [cited by applicant]
US 6458933B1 · Hansen · 2002 [cited by applicant]
US 6486130B1 · Livey et al. · 2002 [cited by applicant]
US 6517838B1 · Hook et al. · 2003 [cited by applicant]
US 6534633B1 · Weidanz et al. · 2003 [cited by applicant]
US 6548067B1 · Seeman et al. · 2003 [cited by applicant]
US 6605711B1 · Valmori et al. · 2003 [cited by applicant]
US 6734013B2 · Schneck et al. · 2004 [cited by applicant]
US 7041442B1 · Kern et al. · 2006 [cited by applicant]
US 7060869B2 · Tsien et al. · 2006 [cited by applicant]
US 7064190B1 · Endl et al. · 2006 [cited by applicant]
US 7074904B2 · Wong et al. · 2006 [cited by applicant]
US 7094555B2 · Kwok et al. · 2006 [cited by applicant]
US 7116407B2 · Hansen et al. · 2006 [cited by applicant]
US 7141656B2 · Rhode et al. · 2006 [cited by applicant]
US 7202349B2 · Davis et al. · 2007 [cited by applicant]
US 7364869B2 · Nixon et al. · 2008 [cited by applicant]
US 7474904B1 · Million-Rousseau et al. · 2009 [cited by applicant]
US 7524503B2 · Khanna et al. · 2009 [cited by applicant]
US 7902121B2 · Chen et al. · 2011 [cited by applicant]
US 8114669B2 · Choo · 2012 [cited by applicant]
US 8268964B2 · Scholler et al. · 2012 [cited by applicant]
US 8298782B2 · Busch et al. · 2012 [cited by applicant]
US 8374468B2 · Jiang · 2013 [cited by applicant]
US 10336808B2 · Schøller · 2019 [cited by examiner]
US 11585806B2 · Pedersen et al. · 2023 [cited by applicant]
US 20020006903A1 · Schneck et al. · 2002 [cited by applicant]
US 20020034513A1 · Rhode et al. · 2002 [cited by applicant]
US 20020058787A1 · Strominger · 2002 [cited by applicant]
US 20020082411A1 · Carter et al. · 2002 [cited by applicant]
US 20020091079A1 · Rhode et al. · 2002 [cited by applicant]
US 20020119149A1 · Jakobsen et al. · 2002 [cited by applicant]
US 20020119162A1 · Nielsen et al. · 2002 [cited by applicant]
US 20020127231A1 · Schneck et al. · 2002 [cited by applicant]
US 20020164340A1 · Brumeanu et al. · 2002 [cited by applicant]
US 20020165364A1 · Tsien et al. · 2002 [cited by applicant]
US 20020198144A1 · Wong et al. · 2002 [cited by applicant]
US 20030017447A1 · Bernardo et al. · 2003 [cited by applicant]
US 20030073102A1 · Kwok et al. · 2003 [cited by applicant]
US 20030096432A1 · Jakobsen · 2003 [cited by applicant]
US 20030104635A1 · Jakobsen · 2003 [cited by applicant]
US 20030118594A1 · Nag et al. · 2003 [cited by applicant]
US 20030171290A1 · Carr et al. · 2003 [cited by applicant]
US 20030199438A1 · Shaw et al. · 2003 [cited by applicant]
US 20030228258A1 · Scheinberg et al. · 2003 [cited by applicant]
US 20040068100A1 · Mach et al. · 2004 [cited by applicant]
US 20040072262A1 · Montero-Julian et al. · 2004 [cited by applicant]
US 20040082012A1 · Busch et al. · 2004 [cited by applicant]
US 20040086520A1 · Diamond · 2004 [cited by applicant]
US 20040137642A1 · Erfle et al. · 2004 [cited by applicant]
US 20040141958A1 · Steinaa et al. · 2004 [cited by applicant]
US 20040143094A1 · Donda et al. · 2004 [cited by applicant]
US 20040204565A1 · Schneck et al. · 2004 [cited by applicant]
US 20040209295A1 · Schwabe et al. · 2004 [cited by applicant]
US 20040209314A1 · Lang et al. · 2004 [cited by applicant]
US 20040223977A1 · Diamond · 2004 [cited by applicant]
US 20040253632A1 · Rhode et al. · 2004 [cited by applicant]
US 20050003431A1 · Wucherpfennig et al. · 2005 [cited by applicant]
US 20050019843A1 · Chen et al. · 2005 [cited by applicant]
US 20050074822A1 · Nixon et al. · 2005 [cited by applicant]
US 20050074848A1 · Schwabe · 2005 [cited by applicant]
US 20050079152A1 · Bot et al. · 2005 [cited by applicant]
US 20050095655A1 · Montero-Julian et al. · 2005 [cited by applicant]
US 20050208529A1 · Winther et al. · 2005 [cited by applicant]
US 20050214284A1 · Price-Schiavi · 2005 [cited by applicant]
US 20050214852A1 · Gaynor et al. · 2005 [cited by applicant]
US 20050239160A1 · Shaw et al. · 2005 [cited by applicant]
US 20060018878A1 · Cooper et al. · 2006 [cited by applicant]
US 20060018929A1 · Zaia et al. · 2006 [cited by applicant]
US 20060073159A1 · Vonderheide et al. · 2006 [cited by applicant]
US 20060078563A1 · Srivastava · 2006 [cited by applicant]
US 20060084116A1 · Muchhal · 2006 [cited by applicant]
US 20060112440A1 · Tsien et al. · 2006 [cited by applicant]
US 20060141540A1 · Miltenyi et al. · 2006 [cited by applicant]
US 20060155115A1 · Jakobsen et al. · 2006 [cited by applicant]
US 20060166214A1 · Kato et al. · 2006 [cited by applicant]
US 20060166875A1 · Jakobsen et al. · 2006 [cited by applicant]
US 20060171954A1 · Endl et al. · 2006 [cited by applicant]
US 20060228758A1 · Muchhal et al. · 2006 [cited by applicant]
US 20060228759A1 · Muchhal et al. · 2006 [cited by applicant]
US 20060234309A1 · Shankar et al. · 2006 [cited by applicant]
US 20060234310A1 · Cai et al. · 2006 [cited by applicant]
US 20060240482A1 · Kwok et al. · 2006 [cited by applicant]
US 20070026503A1 · Lacey · 2007 [cited by applicant]
US 20070134814A1 · Kajander et al. · 2007 [cited by applicant]
US 20070154953A1 · Brunner et al. · 2007 [cited by applicant]
US 20070178532A1 · Jacobson et al. · 2007 [cited by applicant]
US 20070184022A1 · Wang et al. · 2007 [cited by applicant]
US 20070280957A1 · Falk et al. · 2007 [cited by applicant]
US 20080219947A1 · Linette et al. · 2008 [cited by applicant]
US 20080269068A1 · Church et al. · 2008 [cited by applicant]
US 20090004213A1 · Singh et al. · 2009 [cited by applicant]
US 20090061478A1 · Poulsen et al. · 2009 [cited by applicant]
US 20090232766A1 · Wang et al. · 2009 [cited by applicant]
US 20090324630A1 · Jensen · 2009 [cited by applicant]
US 20100159594A1 · Hansen et al. · 2010 [cited by applicant]
US 20100226854A1 · Scholler et al. · 2010 [cited by applicant]
US 20110236411A1 · Scholler et al. · 2011 [cited by applicant]
US 20120020998A1 · Plumas et al. · 2012 [cited by applicant]
DE 19740735A1 · 1999 [cited by applicant]
DE 10247014 · 2004 [cited by applicant]
EP 0106873B1 · 1984 [cited by applicant]
EP 0516953A1 · 1992 [cited by applicant]
EP 0633028B1 · 1995 [cited by applicant]
EP 0636696A1 · 1995 [cited by applicant]
EP 0420913A1 · 1995 [cited by applicant]
EP 0420913B1 · 1995 [cited by applicant]
EP 0423201B1 · 1996 [cited by applicant]
EP 0594772B1 · 1996 [cited by applicant]
EP 0742014A1 · 1996 [cited by applicant]
EP 0946592 · 1999 [cited by applicant]
EP 0949508A1 · 1999 [cited by applicant]
EP 1023319 · 2000 [cited by applicant]
EP 0776339B1 · 2000 [cited by applicant]
EP 1181313 · 2002 [cited by applicant]
EP 0981747B1 · 2002 [cited by applicant]
EP 1227321 · 2002 [cited by applicant]
EP 0630255B1 · 2002 [cited by applicant]
EP 0812331B1 · 2004 [cited by applicant]
EP 0935607B1 · 2004 [cited by applicant]
EP 1437366 · 2004 [cited by applicant]
EP 0877760B1 · 2004 [cited by applicant]
EP 1526141 · 2005 [cited by applicant]
EP 0525821B1 · 2006 [cited by applicant]
EP 0997477B1 · 2006 [cited by applicant]
EP 1017799 · 2006 [cited by applicant]
EP 1349569 · 2007 [cited by applicant]
EP 1012320 · 2007 [cited by applicant]
JP 2001158800A · 2001 [cited by applicant]
RU 2260047 · 2004 [cited by applicant]
RU 2260047C2 · 2005 [cited by applicant]
WO 1989012458 · 1989 [cited by applicant]
WO 1989012459 · 1989 [cited by applicant]
WO 1990004411 · 1990 [cited by applicant]
WO 1991008307A1 · 1991 [cited by applicant]
WO 1991009870 · 1991 [cited by applicant]
WO 199115766A1 · 1991 [cited by applicant]
WO 1991157766 · 1991 [cited by applicant]
WO 1992000055 · 1992 [cited by applicant]
WO 1992008983A1 · 1992 [cited by applicant]
WO 1992018150 · 1992 [cited by applicant]
WO 1992021972 · 1992 [cited by applicant]
WO 1993001498 · 1993 [cited by applicant]
WO 1993001498A1 · 1993 [cited by applicant]
WO 1993004175 · 1993 [cited by applicant]
WO 1993008306 · 1993 [cited by applicant]
WO 1993010220 · 1993 [cited by applicant]
WO 1994011078 · 1994 [cited by applicant]
WO 1994012196 · 1994 [cited by applicant]
WO 1995011998 · 1995 [cited by applicant]
WO 1995012676 · 1995 [cited by applicant]
WO 1995014781 · 1995 [cited by applicant]
WO 1996004314 · 1996 [cited by applicant]
WO 1996026962 · 1996 [cited by applicant]
WO 1996026962A1 · 1996 [cited by applicant]
WO 1997005239 · 1997 [cited by applicant]
WO 1997028191 · 1997 [cited by applicant]
WO 1997035991 · 1997 [cited by applicant]
WO 1997042221 · 1997 [cited by applicant]
WO 1997044667 · 1997 [cited by applicant]
WO 1998003552 · 1998 [cited by applicant]
WO 1998005965 · 1998 [cited by applicant]
WO 1998006749 · 1998 [cited by applicant]
WO 1998005684 · 1998 [cited by applicant]
WO 1999002183A2 · 1999 [cited by applicant]
WO 1999011661 · 1999 [cited by applicant]
WO 1999011775 · 1999 [cited by applicant]
WO 1999014236 · 1999 [cited by applicant]
WO 1999021572 · 1999 [cited by applicant]
WO 1999024577A1 · 1999 [cited by applicant]
WO 1999013095 · 1999 [cited by applicant]
WO 1999036568A2 · 1999 [cited by applicant]
WO 1999042597 · 1999 [cited by applicant]
WO 1999050637 · 1999 [cited by applicant]
WO 1999058557 · 1999 [cited by applicant]
WO 1999060119 · 1999 [cited by applicant]
WO 2000006745 · 2000 [cited by applicant]
WO 2000015665 · 2000 [cited by applicant]
WO 200021989A1 · 2000 [cited by applicant]
WO 2000023053 · 2000 [cited by applicant]
WO 2000057183A1 · 2000 [cited by applicant]
WO 2000075180A2 · 2000 [cited by applicant]
WO 2000078966 · 2000 [cited by applicant]
WO 2001027625A1 · 2001 [cited by applicant]
WO 2001063286A2 · 2001 [cited by applicant]
WO 200173443A2 · 2001 [cited by applicant]
WO 200173443A3 · 2001 [cited by applicant]
WO 2001072782 · 2001 [cited by applicant]
WO 2001072782A2 · 2001 [cited by applicant]
WO 2001070245 · 2001 [cited by applicant]
WO 2001080833 · 2001 [cited by applicant]
WO 2001090198 · 2001 [cited by applicant]
WO 2001090747 · 2001 [cited by applicant]
WO 2002016422 · 2002 [cited by applicant]
WO 2002055992 · 2002 [cited by applicant]
WO 2002054065 · 2002 [cited by applicant]
WO 2002072631 · 2002 [cited by applicant]
WO 2002083903A2 · 2002 [cited by applicant]
WO 2002089837 · 2002 [cited by applicant]
WO 2003000720A1 · 2003 [cited by applicant]
WO 2003016905A2 · 2003 [cited by applicant]
WO 2003031591A2 · 2003 [cited by applicant]
WO 2003072753A2 · 2003 [cited by applicant]
WO 2003073097 · 2003 [cited by applicant]
WO 2003073097A2 · 2003 [cited by applicant]
WO 2002083906 · 2003 [cited by applicant]
WO 2003101473 · 2003 [cited by applicant]
WO 2004000873A2 · 2003 [cited by applicant]
WO 2004014957A1 · 2004 [cited by applicant]
WO 2004018520 · 2004 [cited by applicant]
WO 2004033497 · 2004 [cited by applicant]
WO 2004093905A1 · 2004 [cited by applicant]
WO 2005002621 · 2005 [cited by applicant]
WO 2005003394A2 · 2005 [cited by applicant]
WO 2005007689A1 · 2005 [cited by applicant]
WO 2005035567 · 2005 [cited by applicant]
WO 2005049073 · 2005 [cited by applicant]
WO 2005054860A1 · 2005 [cited by applicant]
WO 2005111624A2 · 2005 [cited by applicant]
WO 2005116051A2 · 2005 [cited by applicant]
WO 2006009838 · 2006 [cited by applicant]
WO 2006009838A2 · 2006 [cited by applicant]
WO 2006014292 · 2006 [cited by applicant]
WO 2006056027A1 · 2006 [cited by applicant]
WO 2006071990A2 · 2006 [cited by applicant]
WO 2006081826 · 2006 [cited by applicant]
WO 2006082387 · 2006 [cited by applicant]
WO 2006082387A1 · 2006 [cited by applicant]
WO 2006090283A2 · 2006 [cited by applicant]
WO 2006113622A2 · 2006 [cited by applicant]
WO 2006130347A2 · 2006 [cited by applicant]
WO 2007015168A2 · 2007 [cited by applicant]
WO 2007065098 · 2007 [cited by applicant]
WO 2007085266A2 · 2007 [cited by applicant]
WO 2007136778A2 · 2007 [cited by applicant]
WO 2008015425A2 · 2008 [cited by applicant]
WO 2008016680A1 · 2008 [cited by applicant]
WO 2008019366A2 · 2008 [cited by applicant]
WO 2008031133 · 2008 [cited by applicant]
WO 2008116468A2 · 2008 [cited by applicant]
WO 2008121836A1 · 2008 [cited by applicant]
WO 2009003492 · 2009 [cited by applicant]
WO 2009003492A1 · 2009 [cited by applicant]
WO 2009003493 · 2009 [cited by applicant]
WO 2009003493A2 · 2009 [cited by applicant]
WO 2009039854A2 · 2009 [cited by applicant]
WO 2009077173A2 · 2009 [cited by applicant]
WO 2009106073A2 · 2009 [cited by applicant]
WO 2009114207 · 2009 [cited by applicant]
WO 2009125231A2 · 2009 [cited by applicant]
WO 2009126816 · 2009 [cited by applicant]
WO 2009126828A2 · 2009 [cited by applicant]
WO 2009155535A2 · 2009 [cited by applicant]
WO 2010009735A2 · 2010 [cited by applicant]
WO 2010032022A2 · 2010 [cited by applicant]
WO 2010037395A2 · 2010 [cited by applicant]
WO 2010037397 · 2010 [cited by applicant]
WO 2010037402A1 · 2010 [cited by applicant]
WO 2012044999A2 · 2012 [cited by applicant]
WO 2012094492A2 · 2012 [cited by applicant]
WO 2015185067A1 · 2015 [cited by applicant]
HLA Nomenclature (2023, 2 pages) (Year: 2023). [cited by examiner]
Liu et al (MHC Complex: Interaction with Peptides. IN: eLS. John Wiley & Sons, Ltd: Chichester, DOI: 10.1002/9780470015902.a0000922.pub2, 2011, pp. 1-12) (Year: 2011). [cited by examiner]
Ali-Khan et al (Curr. Prot. Prot. Sci. 2002, 22.1.1-22.1.19, Suppl. 30, John Wiley & Sons, Inc.) (Year: 2002). [cited by examiner]
Woolhouse et al (Phil. Trans. R. Soc. B, 2012, 367: 2864-2871) (Year: 2012). [cited by examiner]
Schumacher and Schreiber (Science, 2015, 348(6230): 69-74) (Year: 2015). [cited by examiner]
Buonaguro et al (Clin. Vacc. Immunol. 2011, 18(1): 23-34) (Year: 2011). [cited by examiner]
Wieczorek et al (Front. Immunol. 2017, vol. 8, article 292: 1-16) (Year: 2017). [cited by examiner]
Reche and Reinherz (G. Nicosia et al., Eds. ICARIS 2004, LNCS 3239: 189-196) (Year: 2004). [cited by examiner]
Nishioka et al (Front. Immunol. 2018, vol. 9, article 548, pp. 1-6, doi: 10.3389/fimmu.2018.005448) (Year: 2018). [cited by examiner]
Girardi et al (JBC, 2016, 291(20): 10677-10683) (Year: 2016). [cited by examiner]
Kraemer et al (Stem Cell Int. 2015, pp. 1-12, article ID 346714) (Year: 2015). [cited by examiner]
Britannica Online Encyclopedia (Britannica.com/print/article/114462, 2021, 2 pages) (Year: 2021). [cited by examiner]
Denkberg et al (Eur. J. Immunol., 2000, 30: 3522-3532) (Year: 2000). [cited by examiner]
Newell et al (Nature Methods, Jul. 2009, 6(7): 497-500 plus supplementary material, 20 pages) (Year: 2009). [cited by examiner]
Repana et al (Genome Biol. 2019 20: 1-12) (Year: 2019). [cited by examiner]
Wintzingerode et al. Peptide nucleic acid-mediated PCR clamping as a useful supplement in the determination of microbial diversity. Applied and Environmental Microbiology, vol. 66 No. 2, Feb. 2000, pp. 549-557. [cited by applicant]
June, Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007, 117(6), pp. 1466-1476. [cited by applicant]
Demaria et al. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiation Oncology Biol. 63, 3,2005, pp. 655-666. [cited by applicant]
Kozlov, I. et al. Efficient strategies for the conjugation of oligonucleotides to antibodies enabling highly sensitive protein detection. Biopolymers, vol. 73, No. 5, pp. 621-630, 2004. [cited by applicant]
Timmerman et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Research 62, 5845-5852, 2002. [cited by applicant]
Hendrickson et al., “High sensitivity multianalyte immunoassay using covalent DNA-labeled antibiodies and polymerase chain reaction”, Nucleic Acid Res. 1995, vol. 23, No. 3, pp. 522-529. [cited by applicant]
Joerger et al., “Analyte detection with DNA-labeled antibodies and polymerase chain reaction”, Clin. Chem. 41/9, 1371-1377 (1995). [cited by applicant]
Xu et al., “Design of 240,000 orthogonal 25mer DNA barcode probes”. PNAS, Feb. 17, 2009, vol. 106, No. 7, 2289-2294. [cited by applicant]
Altman JD et al. Phenotypic analysis of antigen-specific T lymphocytes. Science, 1996; 274:94-96. [cited by applicant]
Davis MM et al. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334:395-402. [cited by applicant]
Eppstein et al., Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc. Natl. Acad. Sci. USA 82: pp. 3688-3692 (1985). [cited by applicant]
Hansen et al. Phage display of peptide/major histocompatibility class I complexes. European Journal of Immunology, vol. 31, pp. 32-38, 2001. [cited by applicant]
Hwang et al. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study. Proc. Natl. Acad. Sci. USA 77: pp. 4030-4304 (1980). [cited by applicant]
Khurana A. et al. A Method for Production of Recombinant mCD1d Protein in Insect Cells. J Vis Exp. 2007; (10): pp. 1-2. [cited by applicant]
Manz R. et al. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl. Acad. Sci. USA vol. 92:1921-1925 (1995). [cited by applicant]
Morgan RA et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, Oct. 6, 2006 314(5796): 126-129. [cited by applicant]
Pannetier C et al. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today. 1995;16:176-181. [cited by applicant]
Robins HS et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114:4099-4107. [cited by applicant]
Soen Y et al. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoSBiol. 2003; 1:429-438. [cited by applicant]
Stone JD et al. HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. ProcNatlAcadSciUSA. 2005; 102:3744-3749. [cited by applicant]
Xu et al., “Preparation and Characterization of HLA-A 0201 Tretamer Loaded with IE-1 316-324 Antigenic Peptide of Human Cytomegalovirus” Cellular & Molecular Immunology, vol. 3, No. 5, pp. 367-371 (2006). [cited by applicant]
Andersen et al., “Spontaneous cytotoxic T-cell responses against Survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients,” Cancer Res., vol. 61, pp. 5964-5968, Aug. 15, 2001. [cited by applicant]
Bogers et al., “CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection,” Vaccine, Butterworth Scientific, pp. 2974-2984, Aug. 13, 2004 (Aug. 13, 2004), vol. 22, No. 23-24. Guildford, GB. [cited by applicant]
Reznik et al., “A Streptavidin Mutant Useful for Directed Immobilization on Solid Surfaces”, Bioconjugate Chemistry 2001, 12, 1000-1004. [cited by applicant]
Day et al., “Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers”, J Clin Invest. 112: 831-842 (2003). [cited by applicant]
Moon et al., “Naive CD4+ T Cell Frequency Varies for Different Epitopes and Predicts Repertoire Diversity and Response Magnitude”, Immunity, 27, 203-213 (2007). [cited by applicant]
Scriba et al., “Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining”, Journal of Immunology, 2005, 175: 6334-6343. [cited by applicant]
Davis et al., “Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis”, Nature Reviews Immunology, vol. 11, (2011), pp. 551-558. [cited by applicant]
Donolato et al., “On-Chip Manipulation of Protein-Coated Magnetic Beads via Domain-Wall Conduits”, Adv. Mater. 2010, 22, 2706-2710. [cited by applicant]
Degauque et al., “Characterization of Antigen-Specific B Cells Using Nominal Antigen-Coated Flow-Beads”, PLoS One, (2013) vol. 8, Issue 12, pp. 1-10. [cited by applicant]
Drouin et al., Searching for borrelial T-cell epitopes associated with antibiotic-refractory Lyme arthritis,: Molecular Immunology, pp. 2323-2332, Jan. 11, 2008 (Jan. 11, 2008), vol. 45, No. 8, GB. [cited by applicant]
Ed. Charron, “HLA: Genetic diversity of HLA. Functional and Medical Implication,” EDK Press, pages corresponding to Tables 1A and 1B, 1997. [cited by applicant]
Erout et al., “Preparation of Conjugates between Oligonucleotides and N-Vinylpyrrolidone/N-Acryloxysuccinimide Copolymers and Applications in Nucleic Acid Assays to Improve Sensitivity,” Bioconjugate Chem. 1996, pp. 568… [cited by applicant]
Fields, et al., “Solid phase peptide synthesis utilizing 9—fluorenylmethoxycarbonyl amino acids,” Int. J. Peptide Res., 353:161-214, 1990 (Abstract Only). [cited by applicant]
Frayser et al., “Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in [cited by applicant]
Garboczi et al., HLA-A2. peptide complexes: Refolding and crystallization of molecules expressed in [cited by applicant]
Gordon et al., “Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions,” Journal of Medicinal Chemistry, 37 (10):1385-1401, … [cited by applicant]
Haanen et al., “In situ detection of virus-and-tumor-specific T-cell Immunity,” Nature Medicine, Sep. 2000, pp. 1056-1060, vol. 6 (Abastract Only). [cited by applicant]
Hadrup et al., “Persistence of surviving specific T cells for seven years in a melanoma patient during complete remission,” Cancer Biol. Ther., pp. 480-482, May 2006, vol. 5. [cited by applicant]
Houghten et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery,” Nature, 354:84-86, 1991 (Abstract Only). [cited by applicant]
Hughes et al. “Generation and use of alternative multimers of peptide-MHC complexes, ” Journal of Immunological Methods, 268:83-92, 2002. [cited by applicant]
Jung et al., “Multiple Peptide Synthesis Methods and their Applications,” Angewandte Chemie, 31 (4):367-486, 1992 (Abstract Only). [cited by applicant]
Kalandadze et al., “Expression of Recombinant HLA-DR2 molecules,” J. Biol. Chem., pp. 20156-20162, Aug. 16, 1996, vol. 271. [cited by applicant]
Knabel et al., “Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer,” Nature Medicine, Nature Publishing Group, pp. 631-637, Jun. 1, 2002 (Jun. 1, 2002), vol. … [cited by applicant]
König, “Interactions between MHC molecules and co-receptors of the TCR,” Current Opinion in Immunology, pp. 75.83, 2002, vol. 14. [cited by applicant]
Kozono et al., “Production of soluble MHC class II proteins with covalently bound single peptides,” Nature, pp. 151-154, May 12, 1994, vol. 369 (Abstract Only). [cited by applicant]
Kuroda et al., “Analysis of Gas-specific Cytotoxix T Lympocytes in Simian Immunodeficiency Virus-infected Rhesus Monkeys by Cell Staining with Tetrameric Major Histocompatibility Complex Class I-Peptide Complex,” J.Exp.… [cited by applicant]
Kuttler et al., “An algorithm for the Prediction of Proteasomal Cleavages,” J. Miol. Biol., 298:417-429, 2000. [cited by applicant]
Larsson, “Immunocytochemical detection systems,” in Immunocytochemistry: Theory and Practice, pp. 77-145, CRC Press, 1988. [cited by applicant]
Lee et al., “Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients,” Nature Medicine, Jun. 1999, pp. 677-685, vol. 5, No. 6. [cited by applicant]
Lehner, “Allomicrovac: A combined microbicidal -immunising strategy against SIV and HIV infection,” Vaccines for Humans, pp. 64-65, Dec. 5, 2008 (Dec. 5, 2008), XP0025629223, URL biblioteca.porto.ucp.pt-docweb-MULTIMEDI… [cited by applicant]
Ljunggren et al., “Empty MHC class I molecules come out in the cold,” Nature 346:476-480, 1990. [cited by applicant]
Mallone et al., “MHC class II tetramers and the pursuit of antigen-specific T cells: Define, deviate, delete,” Clin. Immunol., pp. 232-242, 2004, vol. 110. [cited by applicant]
Marchand et al., “Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3,” Int. J. Cancer, 63:883-885, 1995. [cited by applicant]
Matsumura et al., “Emerging Principles for the Recognitions of Peptide Antigen by MHC class I Molecules,” Science 257:927-934, 1992. [cited by applicant]
Matsumura et al., “In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from tranfected [cited by applicant]
McCluskey et al., :T-cell activation by purified, soluble, class I MHC molecules: Requiremet for polyvalency, J. Immunol. 141(5): 1451-55, 1988. [cited by applicant]
Mcheyzer-Williams et al., “Tracking antigen-specific helper T cell responses,” Current Opinion in Immunology, pp. 278-284, 1996, vol. 8. [cited by applicant]
Merrifield, et al., “Instrument for Automated Synthesis of peptides,” Analytical Chemistry, 38 (13):1905-1914, 1966 (Abstract Only). [cited by applicant]
Merrifield, “Solid Phase Synthesis,” Science 232:341-347, 1986 (Abstract Only). [cited by applicant]
Meyer et al., “Direct enumeration of Borrelia-reactive CD4 T-cell ex vivo by using MHC class II tetramer,” Proceedings of the National Academy of Sciences of USA. (PNAS), National Academy of Science, pp. 11433-11438, Oc… [cited by applicant]
Mutis et al., “Tetramic HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytoxic T lymphocytes in patients with graft-visus-host disease,” Nature Medic… [cited by applicant]
Neudorfer et al., “Reversible HLA multimers (streptamers) for the isolation of human cytoxic T lympocytes functionally active tumor-and virus-derived antigens,” Journal of Immunolgical Methods, 320:119-131, 2007. [cited by applicant]
O'Herrin et al., “Analysis of the Expression of Peptide-Major Histocompatibility Complexes using high affinity Soluble Divalent T-Cell Receptors,” The Journal of Biological Chemistry, Oct. 20, 1997, pp. 1333-1345, vol. … [cited by applicant]
Reich et al., “Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and enosomal pH: Comparison to class I proteins,” Proc. Natl. Acad. Sci. USA, pp. 2495-2500, Mar. 1997,… [cited by applicant]
Reijonen et al., “Use of HLA class II tetramers in tracking antigen-specific T cell and mapping T-call epitopes,” pp. 282-288, 2003, vol. 29. [cited by applicant]
Scheirle et al., “Peptide binding to soluble HLA-DR4 molecules produced by insect cells,” J. Immunol., pp. 1994-1999, Sep. 15, 1992, vol. 149 (Abstract Only). [cited by applicant]
Sengupta et al., “Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II,” Journal of Immunology, American Association of Immunologists, pp. 1987-1993, Aug. 1, 2004 (Aug. 1, … [cited by applicant]
Shambrook, Fritsch and Maniatis, “Molecular Cloning,” Cold Spring Harbor Press, 1989, Index and Table of Contents pp. xi to xxxviii and 1-1 to 1-47. [cited by applicant]
Shields et al., “The Effect of Human [32—Microglobulin on Major Histocompatibility Complex I Peptide Loading and the Engineering of a High Affinity Variant,” The Journal of Biological Chemistry, Oct. 23, 1998, pp. 28010… [cited by applicant]
Skinner et al., “In situ tetramer staining,” J. Immunol. Meth., pp. 29-34, 2002, vol. 268. [cited by applicant]
Sorensen et al., “Efficient tumor cell lysis mediated by a bcl-X(L) specific T cell clone isolated from a breast cancer patient,” Cancer Immunology, Immunotherapy, Springer, pp. 527-533, Jul. 19, 2006 (Jul. 19, 2006), v… [cited by applicant]
Stern et al., “The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide,” Cell, pp. 465-477, Feb. 7, 1992, vol. 68 (Abstract Only). [cited by applicant]